Pharma

India-Brazil pharma meet highlights Brazil's growing role as a priority market for Indian MSME drugmakers, driven by rising exports, regulatory engagement and demand for specialty medicines

India's drug regulator is withdrawing export NOC requirements for SRA markets and easing other low-risk approvals, even as it strengthens oversight of manufacturing quality

The commerce ministry on Saturday said the country's pharma exports grew 9.4 per cent in 2024-25 to USD 30.47 billion and the industry is aiming for a double-digit expansion in 2026-27. Issues pertaining to pharmaceuticals exports were discussed between the government officials and industry during Chintan Shivir in Ahmedabad. The sector, currently valued around USD 60 billion, is projected to reach USD 130 billion by 2030. India ranks third globally by volume, with medicines exported to over 200 markets, and more than 60 per cent of exports destined for stringent regulatory markets. The US accounts for 34 per cent and Europe for 19 per cent of India's pharmaceutical exports. "The interaction underlined the government's focus on enabling conditions for sustained export acceleration, with industry indicating readiness to target double-digit growth in 2026-27," it said. It added that exporters were also apprised of opportunities arising from recent trade engagements with key partner

Ind-Ra says Indian drugmakers will still see 10% revenue growth in FY27 driven by domestic demand and CDMO traction, despite weaker US sales after Revlimid expiry

AIOCD has urged the Prime Minister to ban AI-generated prescriptions, alleging they are being misused by unregulated e-pharmacies to sell restricted medicines, posing a serious public health risk

India's pharma market is estimated to touch $120 billion by 2030 while Uttar Pradesh accounts for roughly 17 percent of domestic sales

USV, a pharmaceutical and biotechnology company, will acquire a 79 per cent stake in Wellbeing Nutrition at a valuation of Rs 1,583 crore. USV has signed a definitive agreement to acquire a 79 per cent equity stake in Nutritionalab Pvt Ltd, which owns "Wellbeing Nutrition", according to a joint statement. This includes 35 per cent from the founder Avnish Chhabria and 44 per cent from existing shareholders. Its investors -- Early backers Fireside Ventures and Hindustan Unilever -- will divest their collective 40 per cent stake. This Rs 1,583 crores all-cash transaction represents the largest exit in India's health and wellness startup space to date, it added. This strategic expansion of USV, a leading player in diabetes and cardiac care, into consumer wellness is aligned with its expansion across the healthcare continuum. "The addition of Wellbeing Nutrition reinforces USV's evolution into a comprehensive healthcare powerhouse spanning both therapeutic excellence and consumer ...

Domestic device makers warn of safety and dumping risks, while MNC bodies back affordability benefits as the Centre reviews policy on refurbished high-end medical device imports

Zydus Lifesciences posted higher Q3 profit and revenue, aided by strong growth in the US and India businesses, improved margins, and steady momentum in generics, specialty and chronic segments

Draft amendment seeks mandatory reporting of manufacturing and quality changes to drug regulator

The move signals a sharper push towards omnichannel growth amid continued regulatory uncertainty in e-pharmacy

The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets

The deal includes sweeping tariff cuts, expanded services access, enhanced labour mobility and a long-term investment commitment

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

As many as 300 products, including that of engineering goods, pharma, agri, and chemicals, hold huge potential for Indian exporters to push their shipments to Russia as the two countries target USD 100 billion trade by 2030, an official said. At present, India's exports of these goods to Russia stood at USD 1.7 billion, as against Russia's USD 37.4 billion in imports. "This stark disparity demonstrates the substantial complementary export space India can target," the official said, adding increasing exports will also help India bridge its trade deficit with Russia, which stood at USD 59 billion. These high-potential products have been selected by the commerce ministry by analysing complementary basket of products -- mapping India's supply visa-a-vis Russia's demand across key sectors, the official added. The most promising areas mirror India's rising global strengths are engineering goods, pharmaceuticals, chemicals and agriculture, all of which correspond to substantial unmet dema

The dispute centres on Novo Nordisk's Indian patents for semaglutide, which it markets globally as Ozempic and Wegovy for Type 2 diabetes and weight management

Novo Nordisk cut Wegovy prices by up to 37 per cent across different doses to compete with rival drug Mounjaro from Eli Lilly

India’s rupee has fallen to a new low against the US dollar, raising concerns across markets. But analysts say not everyone loses.

Move comes in a bid to gain more space in India's anti-obesity market dominated by Mounjaro

The deal will give Lilly access to Adverum's gene therapy candidate, Ixo-vec, and underscores the U.S. drugmaker's focus on such treatments